81311-83-3Relevant articles and documents
Efficient α-Alkylation of Arylacetonitriles with Secondary Alcohols Catalyzed by a Phosphine-Free Air-Stable Iridium(III) Complex
Panda, Surajit,Saha, Ratnakar,Sethi, Subrat,Ghosh, Rahul,Bagh, Bidraha
, p. 15610 - 15621 (2020/12/01)
A well-defined and readily available air-stable dimeric iridium(III) complex catalyzed α-alkylation of arylacetonitriles using secondary alcohols with the liberation of water as the only byproduct is reported. The α-alkylations were efficiently performed at 120 °C under solvent-free conditions with very low (0.1-0.01 mol %) catalyst loading. Various secondary alcohols including cyclic and acyclic alcohols and a wide variety of arylacetonitriles bearing different functional groups were converted into the corresponding α-alkylated products in good yields. Mechanistic study revealed that the reaction proceeds via alcohol activation by metal-ligand cooperation with the formation of reactive iridium-hydride species.
Stereospecific suzuki cross-coupling of alkyl α-cyanohydrin triflates
He, Anyu,Falck, J. R.
supporting information; experimental part, p. 2524 - 2525 (2010/05/01)
-
Synthesis and Cardiovascular Activity of a New Series of Cyclohexylaralkylamine Derivatives Related to Perhexiline
Leclerc, Gerard,Decker, Nicole,Schwartz, Jean
, p. 709 - 714 (2007/10/02)
A series of 24 cyclohexylaralkylamine derivatives related to perhexilene has been synthesized and screened for cardiovascular activity.All the compounds contained an exocyclic amine which was substituted either by an alkyl, cycloalkyl, or aralkyl group.In the hope of further reducing toxicity, the synthesis of p-tolyl- and p-hydroxyphenyl derivatives 23 and 24 was undertaken.The effect of separating the cyclohexylamine moiety with respect to the aromatic nucleus has been systematically examined.The pharmacological investigations were directed to a search for compounds having an activity better than perhexiline according to the following order of criteria: (1) α-adrenolytic activity; (2) increase of coronary blood flow; (3) calcium antagonism.Several compounds were more potent and exhibited lower toxicity than perhexiline.Further detailed pharmacological investigations (tension time index and decreased cardiac work) have led to the selection of N,2-dicyclohexyl-2-phenethylamine (3) for clinical trials, which are now under way.
